Autor invitado: Dr. Chad Eichman, Gerente de la industria biofarmacéutica Con la nueva tendencia de la industria farmacéutica hacia los tratamientos biológicos, los científicos se enfrentan a la difícil tarea Continue Reading
Is Your LC Column for Biologics Analysis, Truly Bio-Inert?
Let’s talk about column priming and how to address this common concern Guest Author: Chad Eichman, Ph.D., Biopharmaceutical Industry Manager With the emerging trend of biotherapeutics in the pharmaceutical industry, Continue Reading
Large vs Small Organic Molecules in Biopharmaceuticals
Biopharmaceuticals have emerged as the next-gen of therapeutic (large and small) molecules in the pharmaceutical industry Guest Author: Chad Eichman, Ph.D., Biopharmaceutical Industry Manager The pharmaceutical industry has a long-standing Continue Reading
SEC Method Optimization using the Ph. Eur. for Insulin Fibrils
Insulin is a peptide hormone which plays a significant role in metabolism. In its monomer form, insulin can partially misfold, causing a cascade of non-native cross assembly of beta-pleated sheets Continue Reading
Brian Rivera- Product Manager, BioseparationsFeaturedLiquid Chromatography (LC)Pharma / BiopharmaTechnical Tips
Doing HPLC Method Development for Monoclonal Antibody Aggregates? Wait a “SEC”!
By Guest Author: Brian Rivera Contrary to popular belief, size exclusion chromatography (SEC) isn’t straightforward. However, it should be—it’s a non-absorptive separation, right? Just look up an SEC column’s calibration Continue Reading
Transform Your HPLC and UHPLC Method Development Mindset on Analyzing Proteins— Including Monoclonal Antibodies!
A discussion of wide-pore/core-shell technology for monoclonal antibodies, method development considerations with wide-pore/core-shell columns, size exclusion chromatography (SEC) using sub-2 μm particles, and method optimization for SEC. (Webinar sneak peek) Continue Reading